Search

Your search keyword '"Robert L. Atmar"' showing total 339 results

Search Constraints

Start Over You searched for: Author "Robert L. Atmar" Remove constraint Author: "Robert L. Atmar"
339 results on '"Robert L. Atmar"'

Search Results

1. Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trialsResearch in context

2. A single nanobody neutralizes multiple epochally evolving human noroviruses by modulating capsid plasticity

3. Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants

4. Mapping human norovirus antigens during infection reveals the breadth of the humoral immune response

5. Delays in Hepatitis A vaccination in people with HIV in Houston, Texas between 2010 and 2018

6. CLIC and membrane wound repair pathways enable pandemic norovirus entry and infection

7. Risk of COVID-19 after natural infection or vaccinationResearch in context

8. Use of Human Intestinal Enteroids to Evaluate Persistence of Infectious Human Norovirus in Seawater

9. Atomic structure of the predominant GII.4 human norovirus capsid reveals novel stability and plasticity

10. Antiviral Activity of Olanexidine-Containing Hand Rub against Human Noroviruses

11. Performance Analysis of the National Early Warning Score and Modified Early Warning Score in the Adaptive COVID-19 Treatment Trial Cohort

12. New Insights and Enhanced Human Norovirus Cultivation in Human Intestinal Enteroids

13. Genetic Manipulation of Human Intestinal Enteroids Demonstrates the Necessity of a Functional Fucosyltransferase 2 Gene for Secretor-Dependent Human Norovirus Infection

14. Human Norovirus Replication in Human Intestinal Enteroids as Model to Evaluate Virus Inactivation

15. Glycan recognition in globally dominant human rotaviruses

16. Norovirus Protease Structure and Antivirals Development

17. Glycan Recognition in Human Norovirus Infections

18. Bile Goes Viral

19. Human Norovirus Histo-Blood Group Antigen (HBGA) Binding Sites Mediate the Virus Specific Interactions with Lettuce Carbohydrates

20. Human Norovirus Cultivation in Nontransformed Stem Cell-Derived Human Intestinal Enteroid Cultures: Success and Challenges

21. Lack of Norovirus Replication and Histo-Blood Group Antigen Expression in 3-Dimensional Intestinal Epithelial Cells

22. Norwalk Virus Shedding after Experimental Human Infection

23. Norwalk Virus–specific Binding to Oyster Digestive Tissues

24. Stem Cell-Derived Human Intestinal Organoids as an Infection Model for Rotaviruses

26. Histo-Blood Group Antigen Null Phenotypes Associated With a Decreased Risk of Clinical Rotavirus Vaccine Failure Among Children <2 Years of Age Participating in the Vaccine Impact on Diarrhea in Africa (VIDA) Study in Kenya, Mali, and the Gambia

27. Safety and immunogenicity of Multimeric-001 (M-001) followed by seasonal quadrivalent inactivated influenza vaccine in young adults – A randomized clinical trial

28. Temporal Improvements in COVID-19 Outcomes for Hospitalized Adults: A Post Hoc Observational Study of Remdesivir Group Participants in the Adaptive COVID-19 Treatment Trial

29. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial

30. INTRA- AND INTER-HOST EVOLUTION OF HUMAN NOROVIRUS IN HEALTHY ADULTS

31. Evaluating Demographic Representation in Clinical Trials: Use of the Adaptive COVID-19 Treatment Trial (ACTT) as a Test Case

32. A Standardized Antiviral Pipeline for Human Norovirus in Human Intestinal Enteroids Demonstrates No Antiviral Activity of Nitazoxanide

33. Human Sapovirus Replication in Human Intestinal Enteroids

34. Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial

35. Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial

36. Invasive Mold Infections Following Hurricane Harvey—Houston, Texas

37. A Multicenter, Controlled Human Infection Study of Influenza A(H1N1)pdm09 in Healthy Adults

38. Severe Monkeypox in Hospitalized Patients - United States, August 10-October 10, 2022

39. A Multi-Center, Controlled Human Infection Study of Influenza A (H1N1)pdm09 in Healthy Adults

40. New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19

42. A randomized, controlled Phase 1b trial of the Sm-TSP-2 Vaccine for intestinal schistosomiasis in healthy Brazilian adults living in an endemic area

43. Inflammatory syndromes associated with SARS-CoV-2 infection: dysregulation of the immune response across the age spectrum

44. Association of Secretor Status and Recent Norovirus Infection With Gut Microbiome Diversity Metrics in a Veterans Affairs Population

45. Unraveling the Treatment Effect of Baricitinib on Clinical Progression and Resource Utilization in Hospitalized COVID-19 Patients: Secondary Analysis of the Adaptive COVID-19 Treatment Randomized Trial-2

46. Use of Ebola Vaccine: Expansion of Recommendations of the Advisory Committee on Immunization Practices To Include Two Additional Populations - United States, 2021

47. Human norovirus exhibits strain-specific sensitivity to host interferon pathways in human intestinal enteroids

48. An evaluation of cytokine and cellular immune responses to heterologous prime-boost vaccination with influenza A/H7N7-A/H7N9 inactivated vaccine

49. Homologous and Heterologous Covid-19 Booster Vaccinations

50. SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination

Catalog

Books, media, physical & digital resources